NCT05438537 is a clinical trial in Upper Tract Urothelial Cancer, sponsored by Chinese University of Hong Kong.

Who is sponsoring NCT05438537?

NCT05438537 is sponsored by Chinese University of Hong Kong.

What condition does NCT05438537 study?

NCT05438537 studies Upper Tract Urothelial Cancer.

Is NCT05438537 still recruiting?

NCT05438537 is currently recruiting now. Last updated 23 January 2024.

Last reviewed 2024-01-23 · How we verify

NCT05438537

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Comprehensive Prospective Assessment of the Physical and Biological Effects of Upper Tract Urothelial Cancer (UTUC)

Recruiting now Last updated 23 January 2024

What this trial tests

trial in Upper Tract Urothelial Cancer in 300 participants. Currently enrolling.

Timeline

1 November 2021

Primary endpoint
30 December 2030

30 December 2030

Quick facts

Lead sponsor	Chinese University of Hong Kong
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	300
Start date	1 November 2021
Primary completion	30 December 2030
Estimated completion	30 December 2030
Sites	1 location across Hong Kong

Conditions studied

Upper Tract Urothelial Cancer — all drugs for Upper Tract Urothelial Cancer →

Sponsor

Chinese University of Hong Kong

Who can join

18 and older, any sex, with Upper Tract Urothelial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There are many controversies and limitations in the management of Upper Tract Urothelial cancer. A prospective registry is set up for patients in our hospital, aim to have a comprehensive prospective assessment of the physical and biological effects of Upper Tract Urothelial cancer in our patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Upper Tract Urothelial Cancer

Currently open trials in the same condition.

NCT06820255 — DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer. · Phase 4 · recruiting
NCT06987552 — Single-Port RAS Using Da Vinci SP Surgical System for UTUC Patients · NA · recruiting

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05438537 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
Last refreshed: 23 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05438537.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing